Laurie Toich, Assistant Editor

The Better Care Reconciliation Act of 2017 was introduced Thursday.

Trend-in-trend model may predict safety concerns of new drugs.

Non-small cell lung cancer vaccine harnesses peptides to increase immune response.

Novel vaccine improves overall survival in non-small cell lung cancer.

Top news of the day from across the healthcare landscape.

An experimental leukemia drug may increase muscle strength in patients with Duchenne muscular dystrophy.

The Stop Price Gouging Act would hold manufacturers accountable for unjustifiable drug price increases.

Opioid use among Medicaid-insured women 13% higher than the general population.

Glucose-starved immune cells elicit stronger response to cancer cells.

Dabrafenib + trametinib treats patients with unresectable or metastatic melanoma who have a BRAF V600 mutation.

Opioids may have played a role in up to 79% of deaths in Europe in 2015.

BRAF and MEK inhibitors benefit patients with BRAF V600 mutation-positive melanoma.

Top news of the day from across the healthcare landscape.

Specialty drugs must have a proven therapeutic value to be covered by plan sponsors.

The summit provides a place for specialty pharmacy stakeholders to discuss the industry.

Proposed changes to the Quality Payment Program would increase flexibility for clinicians.

Breast Cancer Survivors Foundation settled to pay $350,000 to legitimate breast cancer charities.

Investigational HIV combination drug may improve virologic suppression.

Women experience more severe adverse events related to cardiovascular drugs.

Efficacy of empagliflozin (Jardiance) may be limited to clinical trial population.

Illegally marketed body building supplements may contain steroids.

Methylphenidate (Cotempla XR-ODT) extended-release orally disintegrating tablets approved to treat children with attention-deficit/hyperactivity disorder.

Top news of the day from across the healthcare landscape.

Daily eye drops may increase medication nonadherence in patients with glaucoma.

Consolidation and drug costs will play a key role in the future of specialty pharmacy.

Strategic, operational, and legal hurdles must be conquered before implementing this contract.

Each specialty pharmacy stakeholder has a different definition of value.

Ideal management of specialty drug costs involves an in-depth look at medical and pharmacy claims.

Payers and providers may be less likely to encourage the use of biosimilars due to multiple concerns.

Expert panel at Asembia discusses hurdles in health care reform.